Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-08-28

Clinical Trial Update: An Open-label Phase II Study of Lorvotuzumab Mertansine [Phase 2]

View source ↗

Summary

Open-label Phase II trial of Lorvotuzumab Mertansine (IMG_???), completed with results posted in 2018 for leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lorvotuzumab Mertansine (lorvotuzumab mertansine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2018-08-28